Understanding Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): a comprehensive meta-analysis of clinical characteristics, management, and prognosis compared to MI with the Obstructive Coronary Artery (MIOCA)

Khorasani, Nahid; Mohammadi, Yaser; Sarpoli, Mahdiye; Kazemi, Toba; Riahi, Seyed Mohammad

doi:10.1186/s12872-025-04504-2

Table 4 Comparison of clinical presentation and laboratory findings in MINOCA, MIOCA and control

From: Understanding Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): a comprehensive meta-analysis of clinical characteristics, management, and prognosis compared to MI with the Obstructive Coronary Artery (MIOCA)

Variable		Studies (n)	Pooled Prevalence of each Variable in Study Groups				MIOCA Vs MINOCA (SMD^a,b/OR (95% CI))	P-value for SMD=0/ OR=1	Cochrane Q	I² (%)	P-value for Egger Test
			Sample Size/ Total MIOCA	Pooled Prevalenc in MIOCA(%)	Sample Size/ Total MINOCA	Pooled Prevalenc in MINOCA(%)
Symptoms^c	SA	6	341005/ 153104	21.01 (20.95, 21.08)	176697/ 632172	27.28 (27.17, 27.39)	0.65 (0.42, 1.02)	0.059	8788.96	99.9	0.837
	Syncope	1	108/ 151	71.52 (63.62, 78.56)	14/ 29	48.28 (29.45, 67.47)	2.69 (1.2, 6.05)	0.017	NA	NA	NA
	Chest Pain	10	15658/ 24474	64.15 (63.54, 64.75)	7728/ 11576	67.05 (66.18, 67.92)	1.09 (0.76, 1.57)	0.634	105.63	91.5	0.221
	CP Typical	4	797/ 3170	24.79 (23.3, 26.31)	562/ 3632	14.83 (13.68, 16)	1.66 (1.25, 2.21)	0.001>	11.21	73.2	0.125
	CP Atypical	5	166168/ 1530547	10.57 (10.52, 10.62)	195597/ 626390	31.06 (30.95, 31.18)	0.58 (0.47, 0.72)	0.001>	1551.0	99.7	0.399
	No CP	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Non-Cardiac CP	3	562/ 3107	14.34 (13.13, 15.6)	567/ 3366	14.81 (13.62, 16.03)	1.1 (0.59, 2.04)	0.769	20.05	90	0.852
	Non-Anginal CP	2	88321/ 275334	32.04 (31.87, 32.22)	116313/ 386235	30.07 (29.93, 30.22)	0.96 (0.66, 1.39)	0.817	3.11	67.9	0.001>
	Dyspnea	6	795/ 4346	16.78 (15.68, 17.91)	538/ 3265	15.85 (14.58, 17.16)	0.64 (0.37, 1.11)	0.115	33.84	85.2	0.45
ECG data^c	STE	32	210205/ 1440978	13.43 (13.37, 13.48)	5334/ 254920	0.92 (0.87, 0.96)	3.39 (1.96, 5.87)	0.001>	7174.19	99.6	0.028
	STD	8	6602/ 34101	18.66 (18.25, 19.08)	637/ 2780	21 (19.48, 22.56)	1.19 (0.74, 1.93)	0.477	89.23	92.2	0.597
	EF (%)	23	NA	NA	NA	NA	-0.38 (-0.5, -0.27)	0.001>	1701.19	98.7	0.224
Vital Sign^a,b	SBP	14	NA	NA	NA	NA	0.01 (-0.06, 0.07)	0.815	45.40	71.4	0.667
Vital Sign^a,b	DBP	9	NA	NA	NA	NA	-0.01 (-0.07, 0.06)	0.892	15.20	47.4	0.961
Laboratory data^a,b	LDL (mg/dl)	26	NA	NA	NA	NA	0.18 (0.36, 0.002)	0.053	968.35	97.4	0.079
	HDL (mg/dl)	19	NA	NA	NA	NA	-0.25 (-0.38, -0.12)	0.001>	280.66	93.6	0.972
	TG (mg/dl)	19	NA	NA	NA	NA	0.02 (-0.09, 0.14)	0.702	159.84	88.7	0.919
	TC (mg/dl)	17	NA	NA	NA	NA	0.17 (0.37, 0.02)	0.043	423.92	96.2	0.353
	GFR	18	NA	NA	NA	NA	-0.08 (-0.13, -0.02)	0.84	104.21	83.7	0.078
	CRP (mg/dl)	7	NA	NA	NA	NA	-0.01 (-0.08, 0.1)	0.048	9.78	38.7	0.146
	Cr (mg/dl)	16	NA	NA	NA	NA	0.11 (0.03, 0.18)	0.062	50.58	70.3	0.298
	Hb (mg/dl)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Platelets (10⁹/L)	3	NA	NA	NA	NA	-0.02 (-0.14, 0.09)	0.667	0.34	0	0.35
	Troponin (IU/L)	5	NA	NA	NA	NA	-0.37 (-1.28, 0.53)	0.422	555.2	99.3	0.695
	Troponin-T (IU/L)	6	NA	NA	NA	NA	NA	0.042	1816.88	99.7	0.298
	Troponin-I (IU/L)	6	NA	NA	NA	NA	0.23 (-0.89, 1.35)	0.687	728.32	99.3	0.978
	CK-MB (IU/L)	5	NA	NA	NA	NA	-0.25 (-0.16, 0.35)	0.001>	3.32	0	0.806
	Fibrinogen (g/L)	3	NA	NA	NA	NA	-0.42 (-0.26, 0.58)	0.001>	1.14	0	0.006
	BNP (ng/L)	1	NA	NA	NA	NA	-0.42 (-0.14, 0.71)	0.003	NA	NA	NA

Variable		Studies (n)	Pooled Prevalence of each Variable in Study Groups				MINOCA Vs Control (SMD^a,b/OR (95% CI))	P-value for SMD=0/ OR=1	Cochrane Q	I² (%)	P-value for Egger Test
			Sample Size/ Total MINOCA	Pooled Prevalenc in MINOCA	Sample Size/ Total Control	Pooled Prevalenc in Control
Symptoms^c	SA	1	297/ 8384	3.54 (3.16, 3.96)	281/ 8391	3.35 (2.97, 3.76)	1.06 (0.9, 1.25)	0.492	NA	NA	NA
	Syncope	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Chest Pain	6	9808/ 15644	62.98 (62.22, 63.74)	11052/ 16513	67.1 (66.38, 67.82)	0.88 (0.7, 1.09)	0.239	56.62	91.2	0.505
	CP Typical	5	1993/ 23371	8.45 (8.09, 8.81)	2508/ 30387	8.18 (7.87, 8.49)	0.87 (0.7, 1.1)	0.244	37.11	89.2	0.185
	CP Atypical	4	8112/ 18665	43.44 (42.73, 44.15)	10784/ 24675	43.76 (43.14, 44.38)	0.81 (0.67, 0.99)	0.038	29.73	89.9	0.178
	No CP	2	974/ 2650	36.72 (34.89, 38.57)	1268/ 3299	38.43 (36.77, 40.09)	0.88 (0.56, 1.4)	0.6	17.68	94.3	0.001>
	Non-Cardiac CP	3	4050/ 16967	23.4 (22.77, 24.04)	6666/ 22826	28.92 (28.33, 29.51)	0.66 (0.43, 1.03)	0.068	41.18	95.1	0.787
	Non-Anginal CP	1	202/ 1698	11.9 (10.39, 13.53)	183/ 1849	9.9 (8.57, 11.35)	1.23 (0.99, 1.52)	0.056	NA	NA	NA
	Dyspnea	5	1845/ 22442	7.68 (7.33, 8.04)	1644/ 29121	5.47 (5.21, 5.74)	1.43 (1.29, 1.58)	0.001>	5.81	31.2	0.045
ECG data^c	STE	1	15/ 171	8.77 (4.99, 14.06)	20/ 180	11.11 (6.92, 16.64)	0.77 (0.38, 1.56)	0.466	NA	NA	NA
	STD	1	10/ 171	5.85 (2.84, 10.49)	10/ 180	NA	1.07 (0.43, 2.6)	0.906	NA	NA	NA
	EF (%)	5	NA	NA	NA	NA	-0.07 (-0.19, 0.06)	0.281	1.02	0	0.833
Vital Sign^a,b	SBP	5	NA	NA	NA	NA	0.15 (0.07, 0.23)	0.001>	4.93	18.9	0.15
Vital Sign^a,b	DBP	3	NA	NA	NA	NA	0.04 (-0.1, 0.19)	0.56	1.24	0	0.985
Laboratory data^a,b	LDL (mg/dl)	12	NA	NA	NA	NA	-0.02 (-0.13, 0.1)	0.78	54.69	79.9	0.483
	HDL (mg/dl)	10	NA	NA	NA	NA	-0.2 (-0.28, -0.12)	0.001>	15.05	40.2	0.608
	TG (mg/dl)	7	NA	NA	NA	NA	0.02 (-0.2, 0.24)	0.873	32.95	81.8	0.08
	TC (mg/dl)	6	NA	NA	NA	NA	-0.01 (-0.24, 0.22)	0.93	26.79	81.3	0.876
	GFR	5	NA	NA	NA	NA	-0.34 (-0.6, -0 1)	0.008	121.64	96.7	0.934
	CRP (mg/dl)	6	NA	NA	NA	NA	0.28 (0.08, 0.48)	0.005	17.79	71.9	0.163
	Cr (mg/dl)	4	NA	NA	NA	NA	0.06 (-0.1, 0.21)	0.462	5.35	44	0.219
	Hb (mg/dl)	4	NA	NA	NA	NA	-0.04 (-0.21, 0.12)	0.619	1.06	0	0.984
	Platelets (10⁹/L)	2	NA	NA	NA	NA	0.01 (-0.19, 0.19)	0.982	0.83	0	0.001>
	Troponin (IU/L)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
	Troponin-T (IU/L)	1	NA	NA	NA	NA	-0.05 (-0.22, 0.11)	0.537	NA	NA	NA
	Troponin-I (IU/L)	1	NA	NA	NA	NA	2.14 (1.6, 2.67)	0.001>	NA	NA	NA
	CK-MB (IU/L)	1	NA	NA	NA	NA	-0.21 (-0.58, 0.16)	0.263	NA	NA	NA
	Fibrinogen (g/L)	1	NA	NA	NA	NA	0.69 (0.31, 1.07)	0.001>	NA	NA	NA
	BNP (ng/L)	1	NA	NA	NA	NA	0.57 (0.29, 0.86)	0.001>	NA	NA	NA

Compares differences in clinical presentations (e.g., chest pain, dyspnea) and lab findings (e.g., LDL, CRP) across the three groups, supported by statistical metrics
Abbreviations: NA Not Available, SA Stable Angina, CP Chest Pain, STE ST Elevation, STD ST Depression, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, LDL Low-Density Lipoprotein, HDL High-Density Lipoprotein, TG Triglyceride, TC Total Cholesterol, GFR Glomerular Filtration Rate, CRP C-Reactive Protein, Cr Creatinine, Hb Hemoglobin, IU/L International Unit per Liter, CK-MB Creatinine Kinase-Myocardial Infarction, BNP Brain Natriuretic Peptide, EF (ventricular) Ejection Fraction
a = polled effect for quantitative values, was reported by SMD (An SMD of zero means no considerable effects. SMDs greater than zero indicate direct effect, and SMDs less than zero indicate inverse effect [19]. Cohen offered the following guidelines for interpreting the magnitude of the SMD in the social sciences: small, SMD = 0.2; medium, SMD = 0.5; and large, SMD = 0.8 [126]).
b = polled effect for quantitative values-was reported by SMD
c = Polled effect for qualitative values-was reported by OR
P values less than 0.05 were considered statistically significant

Back to article page

ISSN: 1471-2261

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Cardiovascular Disorders

Contact us